These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
692 related items for PubMed ID: 16602113
21. Prevalence and clinical features of common LRRK2 mutations in Australians with Parkinson's disease. Huang Y, Halliday GM, Vandebona H, Mellick GD, Mastaglia F, Stevens J, Kwok J, Garlepp M, Silburn PA, Horne MK, Kotschet K, Venn A, Rowe DB, Rubio JP, Sue CM. Mov Disord; 2007 May 15; 22(7):982-9. PubMed ID: 17427941 [Abstract] [Full Text] [Related]
24. LRRK2 mutations are a common cause of Parkinson's disease in Spain. Mata IF, Ross OA, Kachergus J, Huerta C, Ribacoba R, Moris G, Blazquez M, Guisasola LM, Salvador C, Martinez C, Farrer M, Alvarez V. Eur J Neurol; 2006 Apr 15; 13(4):391-4. PubMed ID: 16643318 [Abstract] [Full Text] [Related]
26. Rapidly progressive multiple system atrophy in a patient carrying LRRK2 G2019S mutation. Carrer T, Bonato G, Sandre M, Emmi A, Campagnolo M, Musso G, Carecchio M, Parchi P, Antonini A. Neurol Sci; 2024 Jan 15; 45(1):309-313. PubMed ID: 37752324 [Abstract] [Full Text] [Related]
35. [Clinical molecular genetics for PARK8 (LRRK2)]. Tomiyama H, Hatano T, Hattori N. Brain Nerve; 2007 Aug 15; 59(8):839-50. PubMed ID: 17713120 [Abstract] [Full Text] [Related]
36. Cognitive and behavioral symptoms in Parkinson's disease patients with the G2019S and R1441G mutations of the LRRK2 gene. Somme JH, Molano Salazar A, Gonzalez A, Tijero B, Berganzo K, Lezcano E, Fernandez Martinez M, Zarranz JJ, Gómez-Esteban JC. Parkinsonism Relat Disord; 2015 May 15; 21(5):494-9. PubMed ID: 25840672 [Abstract] [Full Text] [Related]
37. Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. Khan NL, Jain S, Lynch JM, Pavese N, Abou-Sleiman P, Holton JL, Healy DG, Gilks WP, Sweeney MG, Ganguly M, Gibbons V, Gandhi S, Vaughan J, Eunson LH, Katzenschlager R, Gayton J, Lennox G, Revesz T, Nicholl D, Bhatia KP, Quinn N, Brooks D, Lees AJ, Davis MB, Piccini P, Singleton AB, Wood NW. Brain; 2005 Dec 15; 128(Pt 12):2786-96. PubMed ID: 16272164 [Abstract] [Full Text] [Related]
38. LRRK2 in Parkinson's disease: genetic and clinical studies from patients. Kumari U, Tan EK. FEBS J; 2009 Nov 15; 276(22):6455-63. PubMed ID: 19804413 [Abstract] [Full Text] [Related]
39. The LRRK2 R1441C mutation is more frequent than G2019S in Parkinson's disease patients from southern Italy. Criscuolo C, De Rosa A, Guacci A, Simons EJ, Breedveld GJ, Peluso S, Volpe G, Filla A, Oostra BA, Bonifati V, De Michele G. Mov Disord; 2011 Aug 01; 26(9):1733-6. PubMed ID: 21538529 [Abstract] [Full Text] [Related]
40. Comprehensive screening of a North American Parkinson's disease cohort for LRRK2 mutation. Johnson J, Paisán-Ruíz C, Lopez G, Crews C, Britton A, Malkani R, Evans EW, McInerney-Leo A, Jain S, Nussbaum RL, Foote KD, Mandel RJ, Crawley A, Reimsnider S, Fernandez HH, Okun MS, Gwinn-Hardy K, Singleton AB. Neurodegener Dis; 2007 Aug 01; 4(5):386-91. PubMed ID: 17622782 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]